Type I Interferon

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study.

A recent investigation into the molecular roots of systemic lupus erythematosus may point the way toward a new generation of therapeutic targets, according to the researchers.